(The TQCC of Leukemia is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms1324
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms1108
MDM2 inhibition: an important step forward in cancer therapy206
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus186
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis181
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation176
SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells167
Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future?163
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis161
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey153
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances150
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments126
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia115
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis111
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies109
Molecular biology of Hodgkin lymphoma104
Risk factors for death in 1859 subjects with COVID-1998
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)97
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms96
Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking95
Hematological features of persons with COVID-1994
Advances in understanding of angioimmunoblastic T-cell lymphoma88
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma87
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network82
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leuk80
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies76
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia76
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia76
Therapeutic implications of menin inhibition in acute leukemias75
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML75
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 974
Catch me if you can: how AML and its niche escape immunotherapy72
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) In72
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?72
Development of CAR-T cell therapies for multiple myeloma71
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials71
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab66
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib66
COVID-19 in persons with chronic myeloid leukaemia66
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma66
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape65
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years64
SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia64
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia64
Base-edited CAR T cells for combinational therapy against T cell malignancies63
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment62
Genome instability in multiple myeloma61
Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors60
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)59
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views58
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia58
Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network58
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study58
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells57
NK-/T-cell lymphomas57
CXCR4 in Waldenström’s Macroglobulinema: chances and challenges57
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study57
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis54
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS54
An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner54
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy53
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial53
The WHO Classification of Haematolymphoid Tumours53
Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells53
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)52
Current challenges and unmet medical needs in myelodysplastic syndromes51
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia51
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study51
High-risk additional chromosomal abnormalities at low blast counts herald death by CML51
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival51
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial51
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma51
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study51
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial51
New strategies to treat AML: novel insights into AML survival pathways and combination therapies50
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations50
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial49
Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease49
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial49
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia48
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis47
Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network47
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL063146
Decrease post-transplant relapse using donor-derived expanded NK-cells45
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant45
HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions45
Treatment resistance in diffuse large B-cell lymphoma45
Second cancer incidence in CLL patients receiving BTK inhibitors44
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey44
Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression44
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis44
N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression44
Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion44
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial44
Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases44
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma43
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA43
COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter43
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma43
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results43
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States43
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b42
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT42
Germline variants drive myelodysplastic syndrome in young adults41
Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study41
Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy41
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia41
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance41
Targeting nuclear import and export in hematological malignancies40
Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma40
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of th39
Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)39
Folate metabolism: a re-emerging therapeutic target in haematological cancers39
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial39
The KMT2A recombinome of acute leukemias in 202338
Complex landscape of alternative splicing in myeloid neoplasms38
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML38
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations38
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results37
Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations37
Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy37
Erdheim–Chester disease: a rapidly evolving disease model37
Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group37
Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia36
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia36
Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive thera36
Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas36
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms36
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views36
Imatinib is not a potent anti-SARS-CoV-2 drug36
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib36
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial36
Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection35
Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome35
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL35
Two decades of targeted therapies in acute myeloid leukemia35
COVID-19 among fit patients with CLL treated with venetoclax-based combinations35
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma35
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse35
The mutagenic impact of melphalan in multiple myeloma35
Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs35
Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears35
Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency34
Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia34
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-1934
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL33
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer33
Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia33
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE33
AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome32
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia32
A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis32
Risk of infections in patients with myeloproliferative neoplasms—a population-based cohort study of 8363 patients32
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses32
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets32
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients32
Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells31
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma31
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma31
Adipocytes in hematopoiesis and acute leukemia: friends, enemies, or innocent bystanders?31
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia31
Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis30
Impact of Covid-19 on the treatment of acute myeloid leukemia30
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response30
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia29
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy29
CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas29
Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission29
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease29
RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators29
Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia29
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma29
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma29
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis29
Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma28
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic l28
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease28
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms28
CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study27
The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling27
Current status and future perspectives in targeted therapy of NPM1-mutated AML27
Multiple myeloma and COVID-1927
Hematopoietic stem and progenitor cell signaling in the niche27
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance27
Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing27
IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells27
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis27
Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma27
Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders27
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia26
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines26
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study26
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia26
Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia26
Selective elimination of immunosuppressive T cells in patients with multiple myeloma26
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma26
SARS-CoV-2 antibody responses in patients with acute leukaemia25
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo25
KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements25
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis25
EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia25
TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition25
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL25
Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–201525
Loss of Y and clonal hematopoiesis in blood—two sides of the same coin?25
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence25
Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice25
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia25
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study25
Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL25
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma25
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial25
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies24
Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype24
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients24
Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients24
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy24
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study24
Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia24
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)24
Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research24
Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions24
miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia23
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis23
Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway23
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas23
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting23
IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis23
Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic23
Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death23
APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations23
Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs23
Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial23
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML23
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report23
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)23
SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia23
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration23
Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression23
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries23
STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation23
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia22
TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways22
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial22
DPP4+ exosomes in AML patients’ plasma suppress proliferation of hematopoietic progenitor cells22
A modular and controllable T cell therapy platform for acute myeloid leukemia22
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission22
Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality22
U2af1 is required for survival and function of hematopoietic stem/progenitor cells22
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies22